Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report

20.10.2023

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2023, which covers the results of its business activities for the first nine months of 2023. 

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended September 30, 2023 amounted to CHF 316 mn (loss of CHF 323 mn in the same period 2022). In the third quarter a loss of CHF 48 mn (profit of CHF 210 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG’s interim report as at September 30, 2023 is available under report.bbbiotech.ch/Q323 or www.bbbiotech.com.

For further information:

Media Relations
Bellevue Asset Management AG
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch